JP2023523241A5 - - Google Patents
Info
- Publication number
- JP2023523241A5 JP2023523241A5 JP2022564258A JP2022564258A JP2023523241A5 JP 2023523241 A5 JP2023523241 A5 JP 2023523241A5 JP 2022564258 A JP2022564258 A JP 2022564258A JP 2022564258 A JP2022564258 A JP 2022564258A JP 2023523241 A5 JP2023523241 A5 JP 2023523241A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- compound according
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025156540A JP2025186437A (ja) | 2020-04-22 | 2025-09-19 | Hbvの処置のための5員のヘテロアリールカルボキサミド化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063014001P | 2020-04-22 | 2020-04-22 | |
| US63/014,001 | 2020-04-22 | ||
| PCT/US2021/028323 WO2021216656A1 (en) | 2020-04-22 | 2021-04-21 | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025156540A Division JP2025186437A (ja) | 2020-04-22 | 2025-09-19 | Hbvの処置のための5員のヘテロアリールカルボキサミド化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023523241A JP2023523241A (ja) | 2023-06-02 |
| JP2023523241A5 true JP2023523241A5 (cg-RX-API-DMAC10.html) | 2024-05-02 |
| JP7830347B2 JP7830347B2 (ja) | 2026-03-16 |
Family
ID=75919388
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564258A Active JP7830347B2 (ja) | 2020-04-22 | 2021-04-21 | Hbvの処置のための5員のヘテロアリールカルボキサミド化合物 |
| JP2025156540A Pending JP2025186437A (ja) | 2020-04-22 | 2025-09-19 | Hbvの処置のための5員のヘテロアリールカルボキサミド化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025156540A Pending JP2025186437A (ja) | 2020-04-22 | 2025-09-19 | Hbvの処置のための5員のヘテロアリールカルボキサミド化合物 |
Country Status (14)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240089748A (ko) * | 2021-10-20 | 2024-06-20 | 어셈블리 바이오사이언시스, 인크. | 방법 |
| JP2024541124A (ja) * | 2021-10-20 | 2024-11-06 | アセンブリー・バイオサイエンシーズ・インコーポレイテッド | 新規結晶形態 |
| WO2023069544A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023069545A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023069547A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| EP4448492B1 (en) | 2021-12-17 | 2026-03-04 | Reglagene, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
| JP7894535B2 (ja) | 2023-02-28 | 2026-07-23 | レグラジーン、インコーポレイテッド | 健康状態の治療のための小分子を作製および使用するための組成物および方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013006394A1 (en) | 2011-07-01 | 2013-01-10 | Institute For Hepatitis And Virus Research | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
| US9968650B2 (en) | 2011-07-13 | 2018-05-15 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
| AR089671A1 (es) | 2012-01-06 | 2014-09-10 | Janssen R & D Ireland | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| CA2881057C (en) | 2012-08-28 | 2020-10-27 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| NZ704758A (en) | 2012-08-28 | 2018-06-29 | Janssen Sciences Ireland Uc | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| CA2881322A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| HK1215030A1 (zh) | 2012-11-09 | 2016-08-12 | Indiana University Research And Technology Corporation | 用於hbv組裝效應劑的替代用途 |
| CN104918612B (zh) | 2012-12-06 | 2019-10-25 | 巴鲁克斯布隆伯格研究所 | 作为抗hbv感染的抗病毒剂的官能化苯甲酰胺衍生物 |
| HK1217649A1 (zh) | 2012-12-27 | 2017-01-20 | 德雷克塞尔大学 | 針對hbv感染的新型抗病毒劑 |
| JP6466348B2 (ja) | 2013-02-28 | 2019-02-06 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用 |
| HUE033542T2 (en) | 2013-04-03 | 2017-12-28 | Janssen Sciences Ireland Uc | Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B |
| TW202126620A (zh) | 2013-05-17 | 2021-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療b型肝炎藥物的用途 |
| HUE040446T2 (hu) * | 2013-05-17 | 2019-03-28 | Janssen Sciences Ireland Uc | Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére |
| PE20151951A1 (es) | 2013-05-17 | 2015-12-26 | Hoffmann La Roche | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b |
| WO2015011281A1 (en) * | 2013-07-25 | 2015-01-29 | Janssen R&D Ireland | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| ES2748029T3 (es) * | 2014-03-13 | 2020-03-12 | Univ Indiana Res & Tech Corp | Moduladores alostéricos de proteína núcleo de hepatitis B |
| TWI730985B (zh) * | 2015-09-15 | 2021-06-21 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| KR102398439B1 (ko) * | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| TW201806956A (zh) * | 2016-06-29 | 2018-03-01 | 諾維拉治療公司 | 二氮呯酮衍生物及治療b型肝炎感染之方法 |
| AU2017326356A1 (en) * | 2016-09-15 | 2019-04-11 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
| WO2019076358A1 (en) | 2017-10-19 | 2019-04-25 | Js Innopharm (Shanghai) Ltd | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF |
| SG11202104086PA (en) * | 2018-10-22 | 2021-05-28 | Assembly Biosciences Inc | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2021216660A1 (en) * | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
-
2021
- 2021-04-21 AU AU2021261307A patent/AU2021261307B2/en active Active
- 2021-04-21 CN CN202610120828.3A patent/CN122167357A/zh active Pending
- 2021-04-21 MX MX2022013251A patent/MX2022013251A/es unknown
- 2021-04-21 CN CN202511217514.7A patent/CN121248511A/zh active Pending
- 2021-04-21 CN CN202180042939.2A patent/CN115843294B/zh active Active
- 2021-04-21 BR BR112022021419A patent/BR112022021419A2/pt unknown
- 2021-04-21 PH PH1/2022/552815A patent/PH12022552815A1/en unknown
- 2021-04-21 KR KR1020227040228A patent/KR20230005881A/ko active Pending
- 2021-04-21 WO PCT/US2021/028323 patent/WO2021216656A1/en not_active Ceased
- 2021-04-21 JP JP2022564258A patent/JP7830347B2/ja active Active
- 2021-04-21 AR ARP210101072A patent/AR121905A1/es unknown
- 2021-04-21 IL IL297305A patent/IL297305B1/en unknown
- 2021-04-21 EP EP21725867.2A patent/EP4139292A1/en active Pending
- 2021-04-21 CA CA3180706A patent/CA3180706A1/en active Pending
- 2021-04-21 US US17/920,544 patent/US12655130B2/en active Active
- 2021-04-22 TW TW110114601A patent/TW202206415A/zh unknown
-
2022
- 2022-10-20 MX MX2026003747A patent/MX2026003747A/es unknown
-
2025
- 2025-09-19 JP JP2025156540A patent/JP2025186437A/ja active Pending
-
2026
- 2026-05-28 AU AU2026204148A patent/AU2026204148A1/en active Pending